Carmell Co. (NASDAQ:CTCX) Short Interest Update

Carmell Co. (NASDAQ:CTCX) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 94,200 shares, a decline of 66.8% from the January 31st total of 284,100 shares. Based on an average trading volume of 6,440,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.6% of the shares of the company are short sold.

Institutional Trading of Carmell

A hedge fund recently bought a new stake in Carmell stock. Citadel Advisors LLC bought a new stake in Carmell Co. (NASDAQ:CTCX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 187,565 shares of the company’s stock, valued at approximately $54,000. Citadel Advisors LLC owned 0.90% of Carmell as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 24.22% of the company’s stock.

Carmell Price Performance

NASDAQ CTCX remained flat at $0.24 during trading hours on Friday. 177,589 shares of the company traded hands, compared to its average volume of 8,761,643. Carmell has a 52-week low of $0.20 and a 52-week high of $3.35. The stock has a 50-day moving average of $0.37 and a 200-day moving average of $0.41.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.